NRx Pharma Raises Doubt To Continue As Going Concern

Loading...
Loading...
  • NRx Pharmaceuticals Inc NRXP shares are down Friday as it evaluated whether there are any conditions or events that could raise substantial doubt about its ability to continue as a going concern within one year beyond the date of filing its annual report. 
  • The company has generated no revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. 
  • Related: Monitoring Board Recommends NRx Pharma's Suicidal Bipolar Depression Study To Continue Enrollment.
  • The company depends on obtaining the necessary equity and/or debt financing to continue operations and cannot make any assurances that sales of its lead product, NRX-101, will commence in the near term, or that additional financing will be available to it. 
  • This could negatively impact the company's business and operations and could also reduce the company's operations.
  • As of December 31, 2022, the cash balance was $20.1 million.
  • Price Action: NRXP shares are down 10.58% at $0.6691 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...